GERN
Geron Corporation
$1.36
-$0.03(-2.16%)
59
Overall
60
Value
81
Tech
36
Quality
Market Cap
$695.81M
Volume
10.34M
52W Range
$1.04 - $4.09
Target Price
$3.33
Company Overview
| Mkt Cap | $695.81M | Price | $1.36 |
| Volume | 10.34M | Change | -2.16% |
| P/E Ratio | -4.0 | Open | $1.38 |
| Revenue | $77.0M | Prev Close | $1.39 |
| Net Income | $-174.6M | 52W Range | $1.04 - $4.09 |
| Div Yield | N/A | Target | $3.33 |
| Overall | 59 | Value | 60 |
| Quality | 36 | Technical | 81 |
No chart data available
About Geron Corporation
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.
Sector: Healthcare
Industry: Biotechnology
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | GERN | $1.36 | -2.2% | 10.34M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |